+7-495-626-8046, +7-495-768-0434
понедельник-пятница, 10:00-18:00
Регистрация
|
+7-495-626-8046, +7-495-768-0434 понедельник-пятница, 10:00-18:00 |
Новости | Магазин | Журналы | Контакты | Правила | Доставка |
|
Вход Регистрация |
|||||
Изначально Рекомендации по применению ультразвуковых контрастных препаратов были опубликованы в 2004 г. и посвящены только исследованиям печени. Второе издание Рекомендаций 2008 г. отражало изменения в диапазоне доступных ультразвуковых контрастных препаратов и обновления рекомендаций по исследованию печени, а также по некоторым непеченочным применениям. С течением времени стала очевидной необходимость в международных рекомендациях по применению ультразвуковых контрастных препаратов для исследования печени. Настоящий документ представляет собой третье издание Рекомендаций по ультразвуковому исследованию печени с контрастным усилением с применением специальных контрастных методик визуализации. Эта совместная инициатива WFUMB-EFSUMB привлекла экспертов из основных ультразвуковых ассоциаций в мире. Эти Рекомендации по ультразвуковому исследованию печени с контрастным усилением одновременно публикуются в официальных журналах обеих федераций (Ultrasound in Medicine and Biology - WFUMB, Ultraschall in der Medizin (European Journal of Ultrasound) - EFSUMB). Эти Рекомендации дают общие советы по применению всех доступных в настоящее время ультразвуковых контрастных препаратов. Они предназначены для создания на международной основе стандартных протоколов по применению и назначению ультразвуковых контрастных препаратов при исследованиях печени и улучшению тактики ведения пациентов.
Ключевые слова:
диагностика, метастазы, гепатоцеллюлярный рак, очаговая узловая (нодулярная) гиперплазия, гемангиома, микропузырьки, diagnosis, metastases, hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, microbubbles
Литература:
1.Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, Majno P, Engerran L. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997;225:51-60. discussion -2.
2.Albrecht T, Blomley M, Bolondi L, Claudon M, Correas JM, Cosgrove D, Greiner L, Jager K, Jong ND, Leen E, Lencioni R, Lindsell D, Martegani A, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med 2004;25:249-256.
3.Arita J, Hasegawa K, Takahashi M, Hata S, Shindoh J, Sugawara Y, Kokudo N. Correlation between contrast-enhanced intraoperative ultrasound using Sonazoid and histologic grade of resected hepatocellular carcinoma. AJR Am J Roentgenol 2011;196:1314-1321.
4.Averkiou M, Powers J, Skyba D, Bruce M, Jensen S. Ultrasound contrast imaging research. Ultrasound Q 2003;19:27-37.
5.Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): Comments on AASLD guidelines. J Hepatol 2012;57:930-932.
6.Bernatik T, Seitz K, Blank W, Schuler A, Dietrich CF, Strobel D. Unclear focal liver lesions in contrastenhanced ultrasonography-lessons to be learned from the DEGUM multicenter study for the characterization of liver tumors. Ultraschall Med 2010;31:577-581.
7.Berstad AE, Brabrand K, Foss A. Clinical utility of microbubble contrast-enhanced ultrasound in the diagnosis of hepatic artery occlusion after liver transplantation. Transpl Int 2009;22:954-960.
8.Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, Venturi AM, Piscaglia F. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42:27-34.
9.Boozari B, Soudah B, Rifai K, Schneidewind S, Vogel A, Hecker H, Hahn A, Schlue J, Dietrich CF, Bahr MJ, Kubicka S, Manns MP, Gebel M. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study. Dig Liver Dis 2011;43:484-190.
10.Bos LJ, Piek JJ, Spaan JA. Background subtraction from time-intensity curves in videodensitometry: a pitfall in flow assessment using contrast echocardiography. Ultrasound Med Biol 1995;21: 1211-1218.
11.Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
12.Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
13.Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-130.
14.Cantisani V, Ricci P, Erturk M, Pagliara E, Drudi F, Calliada F, Mortele K, D''Ambrosio U, Marigliano C, Catalano C, Marin D, Di Seri M, Longo F, Passariello R. Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue(R) low mechanical index real time-enhanced US as compared with multidetector-CTor Gd-BOPTA-MRI. Ultraschall Med 2010;31:500-505.
15.Cao BS, Li XL, Li N, Wang ZY. The nodular form of hepatic tuberculosis: contrast-enhanced ultrasonographic findings with pathologic correlation. J Ultrasound Med 2010;29:881-888.
16.Catalano O, Sandomenico F, Nunziata A, Raso MM, Vallone P, Siani A. Transient hepatic echogenicity difference on contrast-enhanced ultrasonography: sonographic sign and pitfall. J Ultrasound Med 2007;26:337-345.
17.Catalano O, Sandomenico F, Raso MM, Siani A. Low mechanical index contrast-enhanced sonographic indings of pyogenic hepatic abscesses. AJR Am J Roentgenol 2004;182:447-450.
18.Cervone A, Sardi A, Conaway GL. Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions. Am Surg 2000;66:611-615.
19.Chami L, Lassau N, Malka D, Ducreux M, Bidault S, Roche A, Elias D. Beneits of contrast-enhanced sonography for the detection of liver lesions: comparison with histologic findings. AJR Am J Roentgenol 2008;190:683-690.
20.Charnley RM, Morris DL, Dennison AR, Amar SS, Hardcastle JD. Detection of colorectal liver metastases using intraoperative ultrasonography. Br J Surg 1991;78:45-48.
21.Chen LD, Xu HX, Xie XY, Lu MD, Xu ZF, Liu GJ, Liang JY, Lin MX. Enhancement patterns of intrahepatic cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrastenhanced CT. Br J Radiol 2008;81:881-889.
22.Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, Liu GJ, Wang Z, Lin MX, Lu MD. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010;20:743-753.
23.Chen MH, Dai Y, Yan K, Fan ZH, Yin SS, Yang W, Wu W, Wang YB, Li JY. The role of contrastenhanced ultrasound on the diagnosis of small hepatocellular carcinoma (
24.Chen MH, Wei Y, Yan K, Gao W, Dai Y, Huo L, Yin SS, Zhang H, Poon RT. Treatment strategy to optimize radiofrequency ablation for liver malignancies. J Vasc Interv Radiol 2006b;17:671-683.
25.Chen MH, Yang W, Yan K, Dai Y, Wu W, Fan ZH,Callstrom MR, Charboneau JW. The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radio-frequency ablation. Clin Radiol 2007;62:752-760.
26.Chen MH, Yang W, Yan K, Zou MW, Solbiati L, Liu JB, Dai Y. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients - mathematic model, overlapping mode, and electrode placement process. Radiology2004;232:260-271.
27.Choi D, Lim HK, Lee WJ, Kim SH, Kim YH, Kim SH, Lim JH. Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultrasonography with a microbubble contrast agent. J Ultrasound Med 2003;22:1163-1172.
28.Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D''Onofrio M, Evans DH, Filice C, Greiner L, Jager K, Jong N, Leen E, Lencioni R, Lindsell D, Martegani A, Meairs S, Nolsoe C, Piscaglia F, Ricci P, Seidel G, Skjoldbye B, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med 2008;29:28-44.
29.Clevert DA, Stickel M, Minaifar N, Lohe F, Graeb C, Jauch KW, Reiser M. Contrast-enhanced ultrasound in liver transplant: first results and potential for complications in the postoperative period. Clin Hemorheol Microcirc 2009;43:83-94.
30.Conlon R, Jacobs M, Dasgupta D, Lodge JP. The value of intraoperative ultrasound during hepatic resectioncompared with improved preoperative magnetic resonance imaging. Eur J Ultrasound 2003; 16:211-216.
31.Cosgrove D, Harvey C. Clinical uses of microbubbles in diagnosis and treatment. Med Biol Eng Comput 2009;47:813-826.
32.Cosgrove D, Lassau N. Imaging of perfusion using ultrasound. Eur J Nucl Med Mol Imaging 2010;37(Suppl 1):S65-S85.
33.Crocetti L, Lencioni R, Debeni S, See TC, Pina CD, Bartolozzi C. Targeting liver lesions for radiofrequency ablation: an experimental feasibility study using a CT-US fusion imaging system. Invest Radiol 2008;43:33-39.
34.Dawson P, Cosgrove D, Grainger R. Textbook of contrast media. Oxford: ISIS Medical Media; 1999.
35.De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005;11:6171-6176.
36.Dietrich CF, Averkioui MA, Correas JM, Lassau N, Leen E, Piscaglia F. An EFSUMB introduction into dynamic contrast-enhanced ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med 2012;33:344-351.
37.Dietrich CF, Braden B, Hocke M, Ott M, Ignee A.Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound. J Cancer Res Clin Oncol 2008; 134:635-643.
38.Dietrich CF, Ignee A, Hocke M, Schreiber-Dietrich D, Greis C. Pitfalls and artefacts using contrast enhanced ultrasound. Z Gastroenterol 2011; 49: 350-356.
39.Dietrich CF, Kratzer W, Strobe D, Danse E, Fessl R, Bunk A, Vossas U, Hauenstein K, Koch W, Blank W, Oudkerk M, Hahn D, Greis C. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006;12:1699-1705.
40.Dietrich CF, Mertens JC, Braden B, Schuessler G,Ott M, Ignee A. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007b;45:1139-1145.
41.Dietrich CF, Schuessler G, Trojan J, Fellbaum C, Ignee A. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005;78:704-707.
42.Ding H, Wang WP, Huang BJ, Wei RX, He NA, Qi Q, Li CL. Imaging of focal liver lesions: low-mechanical-index real-time ultrasonography with SonoVue. J Ultrasound Med 2005;24:285-297.
43.Dodd GD 3rd, Memel DS, Zajko AB, Baron RL, Santaguida LA. Hepatic artery stenosis and thrombosis in transplant recipients: Doppler diagnosis with resistive index and systolic acceleration time. Radiology 1994;192:657-661.
44.EFSUMB (European Federation of Societies for Ultrasound in Medicine and Biology). Minimum training recommendations for the practice of medical ultrasound. Ultraschall in Med 2006;27:79-105.
45.EFSUMB (European Federation of Societies for Ultrasound in Medicine and Biology). Minimum training requirements for the practice of Medical Ultrasound in Europe. Ultraschall Med 2010; 31:426-427.
46.Ellsmere J, Kane R, Grinbaum R, Edwards M, SchneiderB, Jones D. Intraoperative ultrasonographyduring planned liver resections: why are we still performing it? Surg Endosc 2007;21:1280-1283.
47.Exuzides A, Main ML, Colby C, Grayburn PA, Feinstein SB, Goldman JH. A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent. JACC Cardiovasc Imaging 2010;3:578-585.
48.Fan ZH, Chen MH, Dai Y, Wang YB, Yan K, Wu W, Yang W, Yin SS. Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology. AJR Am J Roentgenol 2006;186:1512-1519.
49.Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
50.Finlay IG, Meek D, Brunton F, McArdle CS. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 1988;75:641-644.
51.Fioole B, de Haas RJ, Wicherts DA, Elias SG, Scheffers JM, van Hillegersberg R, van Leeuwen MS,Borel Rinkes IH. Additional value of contrast enhanced intraoperative ultrasound for colorectal liver metastases. Eur J Radiol 2008;67:169-176.
52.Flint EW, Sumkin JH, Zajko AB, Bowen A. Duplex sonography of hepatic artery thrombosis after liver transplantation. AJR Am J Roentgenol 1988; 151:481-183.
53.Fong Y. Hepatic colorectal metastasis: current surgical therapy, selection criteria for hepatectomy, and role for adjuvant therapy. Adv Surg 2000;34:351-381.
54.Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
55.Forsberg F, Kuruvilla B, Pascua MB, Chaudhari MH, Merton DA, Palazzo JP, Goldberg BB. Comparing contrast-enhanced color low imaging and pathological measures of breast lesion vascularity.Ultrasound Med Biol 2008;34:1365-1372.
56.Foschi FG, Dall''Aglio AC, Marano G, Lanzi A, Savini P, Piscaglia F, Serra C, Cursaro C, Bernardi M, Andreone P, Stefanini GF. Role of contrastenhanced ultrasonography in primary hepatic lymphoma . J Ultrasound Med 2010;29:1353-1356.
57.Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009;19:1206-1213.
58.Guibal A, Taillade L, Mule S, Comperat E, Badachi Y, Golmard JL, Le Guillou-Buffello D, Rixe O,Bridal SL, Lucidarme O. Noninvasive contrastenhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology 2010; 254:420-429.
59.Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoidenhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008a;75(Suppl 1):42-47.
60.Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, Takahashi S, Inoue T, Hagiwara S,Chung H, Ueshima K, Maekawa K. Differential diagnosis of hepatic tumors: value of contrastenhanced harmonic sonography using the newly developed contrast agent. Sonazoid. Intervirology 2008b;51(Suppl 1):61-69.
61.Hirche TO, Ignee A, Hirche H, Schneider A, Dietrich CF. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver Int 2007;27:748-757.
62.Huang D, Chen Y, Li K, Zhang Q. Hemodynamic changes on color Doppler flow imaging and intravenous contrast-enhanced ultrasound for assessing transplanted liver and early diagnosis of complications. J Huazhong Univ Sci Technolog Med Sci 2008; 28:284-286.
63.Iavarone M, Sangiovanni A, Forzenigo LV, Massironi S, Fraquelli M, Aghemo A, Ronchi G, Biondetti P, Roncalli M, Colombo M. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology 2010;52:1723-1730.
64.Ignee A, Piscaglia F, Ott M, Salvatore V, Dietrich CF. A benign tumour of the liver mimicking malignant liver disease-cholangiocellular adenoma. Scand J Gastroenterol 2009;44:633-636.
65.Inoue T, Kudo M, Hatanaka K, Takahashi S, Kitai S, Ueda T, Ishikawa E, Hagiwara S, Minami Y, Chung H, Ueshima K, Maekawa K. Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrastenhanced ultrasonography with sonazoid. Comparison with superparamagnetic iron oxide magnetic resonance images. Oncology 2008;75(Suppl 1): 48-54.
66.International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-664.
67.Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, Abu-Elmagd K, Marsh W, Madariaga J, Mazariegos G, Geller D, Bonham CA, Gayowski T, Cacciarelli T, Fontes P, Starzl TE, Fung JJ. Longterm survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232:490-500.
68.Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrastenhanced US: comparison with histologic differentiation. Radiology 2007;244:898-906.
69.Jarnagin WR, Bach AM, Winston CB, Hann LE, Heffernan N, Loumeau T, DeMatteo RP, Fong Y, Blumgart LH. What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease? J Am Coll Surg 2001;192: 577-583.
70.Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical Phase III and beyond. Recent Results Cancer Res 2010;180: 137-163.
71.Khawaja OA, Shaikh KA, Al-Mallah MH. Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents. Am J Cardiol 2010;106:742-747.
72.Kisaka Y, Hirooka M, Kumagi T, Uehara T, Hiasa Y, Kumano S, Tanaka H, Michitaka K, Horiike N, Mochizuki T, Onji M. Usefulness of contrastenhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006;26:1241-1247.
73.Konopke R, Bunk A, Kersting S. Contrast-enhanced ultrasonography in patients with colorectal liver metastases after chemotherapy. Ultraschall Med 2008;29(Suppl 4):S203-S209.
74.Konopke R, Kersting S, Bergert H, Bloomenthal A, Gastmeier J, Saeger HD, Bunk A. Contrastenhanced ultrasonography to detect liver metastases: A prospective trial to compare transcutaneous un-enhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy. Int J Colorectal Dis 2007;22:201-207.
75.Korenaga K, Korenaga M, Furukawa M, Yamasaki T, Sakaida I. Usefulness of Sonazoid contrastenhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 2009;44:733-741.
76.Kudo M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010;25:439-452.
77.Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T. Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011a;106:368-370.
78.Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010; 78(Suppl 1):40-45.
79.Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011b;29:339-364.
80.Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(Suppl 1):2-15.
81.Kurt M, Shaikh KA, Peterson L, Kurrelmeyer KM, Shah G, Nagueh SF, Fromm R, Quinones MA, Zoghbi WA. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol 2009;53:802-810.
82.Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclere J, Roche A, Lassau N. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006;42:2472-2479.
83.Langnas AN, Marujo W, Stratta RJ, Wood RP, Shaw BW Jr. Vascular complications after orthotopic liver transplantation. Am J Surg 1991;161: 76-82; discussion-3.
84.Larsen LP, Rosenkilde M, Christensen H, Bang N, Bolvig L, Christiansen T, Laurberg S. The value of contrast enhanced ultrasonography in detection of liver metastases from colorectal cancer: a prospective double-blinded study. Eur J Radiol 2007; 62:302-307.
85.Lassau N, Chami L, Chebil M, Benatsou B, Bidault S, Girard E, Abboud G, Roche A. Dynamic contrastenhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med 2011;11:18-24.
86.Lassau N, Chami L, Koscielny S, Chebil M, Massard C, Benatsou B, Bidault S, Ciofi A, Blay JY, Le Cesne A. Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs 2012;30:765-771.
87.Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrastenhanced ultrasonography. Clin Cancer Res 2010a;16:1216-1225.
88.Lassau N, Koscielny S, Chami L, Chebil M, Benatsou B, Roche A, Ducreux M, Malka D, Boige V. Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification-Preliminary Results. Radiology 2010b;258:291-300.
89.Lassau N, Lamuraglia M, Chami L, Leclere J, Bonvalot S, Terrier P, Roche A, Le Cesne A. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006;187: 1267-1273.
90.Leen E, Ceccotti P, Moug SJ, Glen P, MacQuarrie J, Angerson WJ, Albrecht T, Hohmann J, Oldenburg A, Ritz JP, Horgan PG. Potential value of contrast-enhanced intraoperative ultras
Keywords:
диагностика, метастазы, гепатоцеллюлярный рак, очаговая узловая (нодулярная) гиперплазия, гемангиома, микропузырьки, diagnosis, metastases, hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, microbubbles
